Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
This process includes extensive molecular simulations of the receptor in its native membrane environment, along with ensemble virtual screening that accounts for its conformational mobility. In the case of dimeric or oligomeric receptors, the entire functional complex is modelled, identifying potential binding pockets on and between the subunits to encompass all possible mechanisms of action.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q8N6C5
UPID:
IGSF1_HUMAN
Alternative names:
Immunoglobulin-like domain-containing protein 1; Inhibin-binding protein; Pituitary gland-specific factor 2; p120
Alternative UPACC:
Q8N6C5; B5MEG2; H9KV64; O15070; Q9NTC8
Background:
Immunoglobulin superfamily member 1, also known as Immunoglobulin-like domain-containing protein 1, Inhibin-binding protein, Pituitary gland-specific factor 2, or p120, plays a pivotal role in inhibin signaling. It acts as a coreceptor, modulating the effects of inhibin B and antagonizing activin A signaling, thereby influencing various physiological processes.
Therapeutic significance:
The protein's involvement in Hypothyroidism, central, and testicular enlargement, underscores its potential as a target for therapeutic intervention. Understanding the role of Immunoglobulin superfamily member 1 could open doors to potential therapeutic strategies.